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Abstract
Background: Paraquat ingestion is frequently fatal. While biomarkers of kidney damage increase during paraquat-induced
acute kidney injury (AKI), significant concurrent proteinuria may alter diagnostic thresholds for diagnosis and prognosis
to an unknown extent. This study evaluated the effect of albuminuria on biomarker cutoffs for diagnosis and outcome
prediction.
Methods: This was a multi-centre prospective clinical study of patients following acute paraquat self-poisoning in 5 Sri
Lankan hospitals. Biomarker concentrations were quantified using ELISA and microbead assays and correlated with urinary
albumin. Functional-AKI was defined by the Acute Kidney Injury Network serum creatinine definition and alternatively by
a ≥50% increase in serum cystatin C. Albuminuria was defined as albumin-creatinine ratio >30 mg/g. The study outcomes
were compared with a retrospective analysis of a pre-clinical study of paraquat-induced nephrotoxicity with appropriate
controls.
Results: Albuminuria was detected in 34 of 50 patients, and increased with functional-AKI severity. The concentrations
of uNGAL, uCysC, uClusterin, uβ2M, and uKIM-1 were higher in albuminuric compared to non-albuminuric patients (p
< 0.001). Albuminuria correlated with biomarker concentration (r > 0.6, p < 0.01) and was associated with death (p = 0.
006). Optimal biomarker cutoffs for prediction of death were higher in the albuminuric group. Similar outcomes with
more detailed analysis were obtained in experimental paraquat nephrotoxicity.
Conclusion: Albuminuria was associated with paraquat-induced nephrotoxicity and increased excretion of low-molecular
weight protein biomarkers. AKI biomarker cutoffs for diagnosis, outcome prediction and AKI stratification increased in the
presence of albuminuria. This may lead to over-diagnosis of AKI in conditions independently associated with proteinuria.
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Background
Acute kidney injury (AKI) is common and has diverse
aetiology [1–3]. Nephrotoxic drugs are common contribu-
tory factors to AKI [4]. In Asia, purely nephrotoxic AKI
(ToxAKI) is commonly seen following deliberate ingestion
of agrochemicals [5–8].
AKI definitions have evolved around changes in creatin-
ine or urine output [9, 10], with both measures lacking
specificity and sensitivity for early AKI detection. Further-
more, plasma creatinine concentrations usually respond
only slowly to kidney damage and may be altered by non-
renal mechanisms [11, 12]. Alternative strategies for
defining AKI with kidney-specific structural (injury) bio-
markers have been proposed which may diagnose AKI
earlier and with greater specificity and sensitivity than
creatinine [13–17]. However, structural biomarker-based
definitions also carry several challenges. One of these is
low or absent biomarker concentrations in healthy popu-
lations. If these are normally absent, then the appearance
of any biomarker should herald disease. Alternatively,
reference ranges need to be defined for healthy
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populations and in the presence of co-morbidities. The
majority of studies report biomarker reference ranges in
heterogeneous ill subjects without AKI [18–20] and only a
few studies define (some) biomarker concentrations in
healthy populations [21, 22]. In addition, non-renal factors
that increase structural biomarker concentrations inde-
pendently of renal injury, have not yet been incorporated
into AKI definitions [21–25]. In particular, proteinuria
and albuminuria, both important biomarkers, increase
excretion of urinary Neutrophil gelatinase-associated
lipocalin (NGAL), and urinary cystatin C (uCysC) in crit-
ically ill patients [26].
Our observation of significant proteinuria following
paraquat poisoning prompted analysis of the influence
of proteinuria on the excretion of other renal bio-
markers. We hypothesised that paraquat-induced al-
buminuria would increase the excretion of low
molecular weight protein biomarkers subject to tubu-
lar reabsorption. This was examined in a prospective
clinical study of patients following acute paraquat
ingestion and then in a retrospective analysis of con-
trolled data in an experimental rodent model of para-
quat nephrotoxicity. These studies determined the
effect of albuminuria on biomarker cutoffs for AKI
diagnosis and outcome prediction.
Methods
Clinical study
This multi-centre prospective observational study was
approved by the human research ethics committees of
both the University of New South Wales (Sydney) and
University of Peradeniya (Sri Lanka). The recruitment of
healthy controls was carried out in 3 major provinces
(North Central, Central and Southern Province of Sri
Lanka) where the ‘Sinhala’ ethnic group is predominant;
our patient cohort was also recruited from the hospitals
located in these regions. These areas were selected since
a high incidence of self-poisoning is reported from these
regions. Healthy volunteers from several regions of Sri
Lanka (outside the chronic kidney disease of unknown
origin areas) were asked to volunteer for this study and
informed written consent was obtained. All consenting
volunteers underwent clinical screening and patients
who had a history of any existing clinical conditions
were excluded from this cohort. Single blood and urine
samples were collected to quantify normal biomarker
concentrations. Detail methods of patient recruitment to
this cohort is described elsewhere [12, 27] and the
patient cohort studied in this manuscript is identical to
that discussed previously [12, 27]. Briefly, patients who
presented to adult medical units of 5 study hospitals
with a history of paraquat self-poisoning within 24 h of
ingestion were consented for inclusion in the study.
Patients who were young (age <15 years), or co-ingested
another chemical were excluded. Informed written con-
sent was obtained from all patients or their accompany-
ing relatives. Paraquat ingestion was confirmed by a
positive urine dithionate test four hours after ingestion.
Demographic, clinical, and laboratory data were col-
lected prospectively until discharge. Blood and urine
sampling was scheduled at 4, 8, 16, 24 h after ingestion
and then daily. Collected samples were immediately
processed and stored in −70 °C freezers until batch-wise
assays commenced.
Pre-clinical study
The rodent study was approved by the University
Animal Ethics Committee (Health Sciences) of the Uni-
versity of Queensland and conducted as part of a doc-
toral study by one of the authors, KW at Therapeutic
Research Centre, University of Queensland, Australia.
Raw biomarker data [urinary albumin (uAlb), kidney
injury molecule-1 (uKIM-1), cystatin C (uCysC), clus-
terin (uClu), osteopontin (uOstP), neutrophil gelatinase-
associated lipocalin (uNGAL), beta-2-microglobulin
(uβ2M)] from that study [28] was used to evaluate the
influence of urinary albumin on the excretion of urinary
biomarkers. Detailed methods including animal hand-
ling, paraquat dose, sample collection, biomarker assays,
and histopathology of the original study are described
elsewhere [28]. Briefly, male Wistar rats (200–250 g)
from the Animal Resources Centre (Western Australia,
Australia) were housed on a 12 h light/dark cycle. The
animals were allowed free access to food (standard
laboratory chow) and water. Rats were fasted overnight
(12 h) before the experiments. Control rats (n = 6) were
gavaged with water. The treatment group rats were ran-
domly divided into the 4 dose groups with 6 rats in each
group. These were dosed orally with 4 different doses
(15, 30, 60 and 90 mg/kg) of paraquat dichloride solu-
tions (Sigma-Aldrich, St. Louis, MO, USA). These doses
were approximately 10, 25, 50, and 70% of the LD50 in
rats [28]. After administration, rats were housed in indi-
vidual metabolic cages and urine samples collected on
dry ice at intervals of 0–8 h, 8–24 h and 24–48 h. Blood
was collected from the tail vein at 8 and 24 h. At 48 h,
the rats were sacrificed and blood was collected from
the vena cava. Histopathology grades of 1 to 7 (1-no
changes, 7-severe) were assigned for each rat [28] and
represent the total numbers of necrotic cells and pyk-
notic nuclei in paraquat-treated rats normalised to total
baseline necrotic cells and pyknotic nuclei counted in
the control groups and assigned by KW under the
supervision of two pathologists.
Biomarker assays
Serum creatinine (sCr) was measured using the Jaffe
method (kinetic Jaffe reaction method, rate blank and
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compensated) on Roche Hitachi 912 automatic analyser.
DuoSet ELISA development kits supplied by R&D systems®
were used for quantifying uKIM-1, and uClu. Urinary
interleukin-18 (IL-18) was measured using a commercially
available ELISA kit (Bender MedSystems GmbH, Vienna,
Austria). Intra and inter assay precision for ELISA was <
10%. Other AKI biomarkers such as uCysC, uAlb, trefoil
factor-3 (uTFF3), uOstP, uβ2M and uNGAL were quanti-
fied on the same sample using Bio-Plex Pro™ RBM Human
Kidney Toxicity Assays panel 2 on the Bio-Plex 200 system
(BIO-RAD). Inter and intra assay precision estimates were
<15% and <5% respectively. Rodent samples were assayed
similarly as previously described [28].
Outcome definition and statistical analysis
Biomarker concentrations were reported as absolute con-
centrations and as normalised to urinary creatinine concen-
tration. Albuminuria in patients was defined as urinary
albumin creatinine ratio [(ACR) ≥30 mg/g (μg/mg)] [29,
30]. Albuminuria in the pre-clinical study was defined as
ACR values ≥ 95th centile from control rats since cut-offs
for albuminuria in rats were not available. Functional-AKI
was defined by change in sCr according to the Acute Kid-
ney Injury Network (AKIN) [10] criteria or ≥50% change in
serum cystatin C [31]. Moderate to severe functional-AKI
was defined as an increase in sCr of ≥200% (AKIN Stage 2)
or 300% (AKIN Stage 3) respectively [32]. The 95th centile
of each structural biomarker obtained in healthy volunteers
was defined as the cutoff for structural-AKI. This definition
was modelled on similar approaches to define healthy refer-
ence cutoff points of cardiac troponin for diagnosis and risk
stratification of myocardial injury [33, 34].
Continuous variables were compared using the Wilcoxon
rank sum test and reported as median and interquartile
range. Categorical variables were reported as proportions
and compared using Fisher’s exact test. Correlations were
done using the Spearman rank-order. The prognostic per-
formance of each biomarker for predicting death was evalu-
ated by area under the receiver operating characteristic
curves (AUC-ROC) stratifying to albuminuria and the opti-
mal threshold for each biomarker was calculated. For each
biomarker, the sensitivity and specificity of structural-AKI
for predicting functional-AKI or death was calculated
separately in the presence or absence of albuminuria. The
statistical analyses were conducted using GraphPad Prism
version 6 (GraphPad Software, San Diego, USA) and
STATA IC10 (StataCorp, 2007).
Results
Clinical study findings
Biomarker concentrations in healthy volunteers
Plasma and urinary functional and urinary structural
injury biomarker levels in urine and blood samples from
63 healthy young adult volunteers [median age 28 years
(IQR 26–33), 70% male] are presented as absolute
(Table 1) and normalised concentrations (Additional file
1: Table S1).
Patient baseline demographics according to ACR
The 50 confirmed paraquat-poisoned patients were pre-
viously healthy young adults [median age, 24 years (IQR
19–32, range 15–56)], and 55% male. Baseline demo-
graphic and clinical characteristics were similar for
albuminuric and non-albuminuric groups (Table 2)
except for serum creatinine and paraquat concentra-
tions. Thirty-four (70%) developed albuminuria within
16–24 h. Twenty-six patients developed moderate to
severe functional-AKI (AKI stage 2, n = 7, or stage 3, n
= 19). The incidence of moderate to severe functional-
AKI was higher in albuminuric patients (68% compared
with 25%; p < 0.01). Based on the serum cystatin C defin-
ition of functional-AKI, 19 patients developed functional-
AKI, of these 17 had albuminuria. All 12 deaths occurred
in patients with albuminuria (p < 0.01).
Table 1 Serum and urinary functional and injury biomarkers in
healthy subjects (absolute concentrations)
Biomarkers Median and IQR Lower reference
limit
(5th centile)
Upper reference
limit
(95th centile)
Serum biomarkers
Total protein (g/dl) 6.5 (5.8–7.1) 5.3 8.9
Albumin (g/dl) 4.1 (3.8–4.3) 3.2 5.3
Creatinine
mg/dl 0.82 (0.72–0.94) 0.56 1
μmol/L 72 (64–84) 50 88
Cystatin C (mg/l) 0.84 (0.78–0.88) 0.6 1
Urinary biomarkers
Total protein (mg/L) 196 (161–267) 70 1870
Creatinine
mg/dl 123 (54–182) 33 253
mmol/L 11 (5–16) 3 22
Urea
mg/dl 1432 (822–2023) 444 3206
mmol/l 511 (294–722) 159 1144
Cystatin C (ng/ml) 24 (11–51) 3.8 94
Albumin (ng/ml) 5700 (1700–9200) 500 21000
NGAL (ng/ml) 14.8 (10.2–40.3) 3.4 134
KIM-1 (ng/ml) 0.57 (0.33–1.23) 0.02 2.8
Clusterin (ng/ml) 217 (104–393) 28 798
β2M (ng/ml) 67 (36–139) 14.5 250
Osteopontin (ng/ml) 1400 (400–0.2800) 100 6800
TFF3 (ng/ml) 1400 500–1500) 200 3200
IL-18 (pg/ml) 53.8 (39–80) 39 136
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Albuminuria and functional AKI
ACR increased with functional AKI severity (p < 0.0001,
Fig. 1) and was greater in patients with moderate to
severe functional-AKI compared to the healthy controls
(p < 0.0001). Albuminuria was also observed in 5 pa-
tients who did not develop functional-AKI (based on
either sCr or sCysC definition) but did have increased
structural biomarker concentrations. The median ACR
was higher in paraquat-poisoned subjects without AKI
compared to the healthy controls (p < 0.05) (Fig. 1).
Biomarker concentrations stratified by ACR and AKI
Within 24 h of paraquat ingestion, maximum (normalised)
biomarker concentrations were increased in the presence of
albuminuria. In albuminuric patients, uCysC, uClu,
uNGAL, uKIM-1, and uβ2M increased with increasing AKI
severity (Additional file 2: Figure S1). Concentrations were
lower in patients who did not develop albuminuria. The
concentrations of filtered biomarkers, uCysC, uNGAL,
uClu, uβ2M, uTFF3 and uKIM-1 were higher in albumin-
uric patients than healthy controls (p < 0.001) (Additional
file 2: Figure S1).
Correlation of urinary biomarkers and albuminuria
Normalised uCysC and uClu correlated well with ACR
(r = 0.7, p < 0.0001). Urinary NGAL, β2M, OstP and
KIM-1 also correlated with ACR (r = 0.5, p < 0.01). Cor-
relations with ACR for uIL-18 (r = 0.4, p < 0.05) and
uTFF3 (r = 0.3, p > 0.05) were modest (Fig. 2). A similar
correlation profile was obtained when the absolute urin-
ary concentration of each biomarker was assessed
against absolute uAlb (Additional file 2: Figure S2).
Biomarker threshold for predicting death as an outcome in
the presence of albuminuria
Twelve (n = 12) patients died during the hospital stay
and all had developed albuminuria. No patient without
albuminuria died (p < 0.01). Table 3 summarises the
AUC-ROCs, specificity, sensitivity and the optimal cutoff
for each biomarker to predict death in the albuminuric
group (n = 34, 12 deaths) and for the entire patient co-
hort (n = 50, 12 deaths). There was an almost 2-fold in-
crease in biomarker cut-offs for uCysC, uClu and uβ2M
in the albuminuric cohort with smaller increases in the
cutoffs for the other biomarkers (Table 3). In addition,
biomarker performance was uniformly reduced in the
presence of albuminuria.
Sensitivity and specificity of structural biomarker based
definition in diagnosis of AKI
The sensitivity of the 95th centile in the healthy volun-
teer group of structural biomarkers for diagnosis of
moderate to severe functional-AKI was high amongst
albuminuric patients for both uCysC (sensitivity 96%, CI
79-99%; diagnostic odds ratio = 8, CI 1–91) and uClu
(sensitivity 91%, CI 73–98%; diagnostic odds ratio = 13,
CI 2–82) (Table 4). Similarly, the sensitivity of structural
AKI for predicting death was higher for both uCysC
(sensitivity 92%, CI 64–98%; diagnostic odds ratio = 2, CI
0.2–18) and uClu (sensitivity 83%, CI 55–95%; diagnostic
odds ratio = 2, CI 0.3–11) in patients with albuminuria
(Fig. 3, Table 4). But, the lower end of the confidence
interval for the odds ratios for AKI diagnosis using both
biomarkers in predicting mortality was less than 1. Fur-
thermore, the specificity of these two biomarkers in
diagnosing functional AKI or predicting death was low
(<30%) in patients with albuminuria. In contrast, the
sensitivity for predicting death or diagnosing functional
Table 2 Baseline demographic and clinical characteristics
Baseline characteristics No-albuminuria
(ACR < 30 mg/g)
(n = 16)
Albuminuria
(ACR≥ 30 mg/g)
(n = 34)
p
Age (years) 23 (19–35) 25 (19–32) 0.97
Male gender (%) 60 50 0.5
Weight (kg) 50 (45–55) 50 (39–60) 0.65
Volume ingested (ml) 10 (5–30) 20 (20–50) 0.05
Time to admission
(hours)
4 (2–6) 3.5 (2–7.5) 0.98
Pulse (beats/min) 80 (78–88) 82 (80–89) 0.50
BP systolic (mm Hg) 120 (110–120) 110 (110–120) 0.18
BP diastolic 80 (70–80) 70 (70–80) 0.52
sCr (mg/dl) 0.7 (0.5–0.8) 0.9 (0.7–1.3) 0.006
sCysC (mg/l) 0.7 (0.6–0.8) 0.7 (0.6–0.8) 0.53
Maximum serum
paraquat (ng/ml/24 h)
20 (10–120) 640 (140–1400) 0.0006
Functional-AKI (%) 8 (50%) 29 (85%) 0.007
Death (n) 0 12 0.006
Fig. 1 ACR in healthy controls and patients with or without functional-
AKI. Albuminuria (dark grey shaded area; ACR≥ 30 mg/g); normal ACR
(light grey shaded area, <30 mg/g). AKI is defined based on
AKIN classification
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AKI by uCysC or uClu was low (1%) in non-albuminuric
patients (Fig. 3, Table 4).
Urinary β2-M structural AKI displayed excellent sensi-
tivity for diagnosing functional-AKI in both albuminuric
(sensitivity 91%, CI 73–98%; diagnostic odds ratio = 4, CI
0.5–21) and non-albuminuric subjects (sensitivity 100%,
CI 44–100%). Among 5 albuminuric patients who did
not develop functional-AKI (Fig. 3, Table 4), all had
structural AKI based on sufficient increases in at least
one damage biomarker.
Preclinical study findings
Albuminuria and biomarkers in paraquat treated rats
Urinary albumin concentration increased with severity
of injury (i.e. increased histopathology grade) and with
paraquat dose in rats (Fig. 4). Median urinary albumin
concentrations at 24 h in 15, 30, and 60 mg/kg paraquat
dose group were 35 (IQR 25–49), 45 (IQR 19–86) and
87 (IQR 26–117) μg/ml respectively.
Urinary albumin correlated strongly with uCysC (r =
0.9, p < 0.0001), well with uNGAL (r = 0.7, p < 0.0001),
Fig. 2 Correlation between normalised biomarker concentration and ACR following paraquat poisoning
Table 3 Comparative diagnostic performance of renal biomarkers in predicting death in paraquat poisoning stratified by albuminuria
All patients (n = 50) Patients with albuminuria (n = 34) a p‡
Biomarkers
(ng/mg Cr)
AUC-ROC
(95% CI)
Cut-off Sensitivity
(95% CI)
Specificity
(95% CI)
AUC-ROC
(95% CI)
Cutoff Sensitivity
(95% CI)
Specificity
(95% CI)
uCysC 0.78
(0.62–0.94)
>200 67 (35–90) 67 (50–82) 0.68
(0.49–0.88)
>300 67 (35–90) 66 (43–84) 0.46
uClu 0.70
(0.52–0.87)
>750 67 (34–90) 60 (42–75) 0.55
(0.34–0.76)
>1600 58 (28–74) 59 (36–80) 0.29
Uβ2M 0.68
(0.48–0.88)
>990 67 (35–90) 68 (50–82) 0.60
(0.39–0.82)
>1280 67 (35–90) 68 (45–86) 0.62
uNGAL 0.81
(0.67–0.95)
>80 67 (35–90) 68 (50–82) 0.75
(0.56–0.93)
>90 67 (35–90) 68 (45–86) 0.60
uKIM-1 0.75
(0.57–0.90)
>0.96 75 (43–94) 73 (56–85) 0.61
(0.41–0.82)
>1.3 67 (35–90) 40–83) 0.38
uTFF3 0.85
(0.72–0.98)
>2340 75 (43–94) 71 (52–85) 0.82
(0.67–0.97)
>2830 75 (43–94) 70 (46–88) 0.74
uOstP 0.82 (0.68–0.97) >1760 75 (42–94) 70 (53–84) 75 (57–94) >2100 75 (42–94) 68 (45–86) 0.60
uIL-18
(pg/mg Cr)
64 (45–82) >130 63 (31–89) 60 (42–75) 55 (34–76) >130 63 (31–89) 50 (28–72) 0.54
a Albuminuria; ACR ≥ 30 mg/g, All normalised biomarker concentrations are presented in ng/mg Cr except uIL-18 (pg/mg Cr)
‡The AUC-ROC values were compared using Delong method
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uKIM-1 (r = 0.6, p < 0.01), and uβ2M (r = 0.7, p < 0.001),
but not with uOstP (r = 0.3, p < 0.05) or uClu (r = 0.3, p
< 0.05) (Additional file 2: Figure S3). Correlations of
similar magnitude were also observed after normalising
the biomarker concentrations to urinary creatinine
(Additional file 2: Figure S4).
Biomarker concentrations at 24 h in paraquat treated rats
based on albuminuria
The 95th centile ACR from control rats used to define
albuminuria was 115 μg/mg Cr. Albuminuria was
associated with increased concentrations of uβ2M,
uCysC, uOstP, and uKIM-1 in paraquat treated rats
(Fig. 5; p < 0.05).
Discussion
This study demonstrated that paraquat toxicity was as-
sociated with development of albuminuria in clinical and
experimental nephrotoxicity. In turn, albuminuria was
associated with increased excretion of renal biomarkers
and modified biomarker sensitivity in outcome predic-
tion. The data confirm that concentrations of the low
molecular weight protein biomarkers, CysC, OstP, β2M,
KIM-1 and NGAL increased in the presence of albumin-
uria. Albuminuria was also associated with mortality. To
our knowledge, this is the first study to evaluate the
influence of albuminuria on excretion of all Predictive
Safety Testing Consortium (PSTC) qualified urinary
biomarkers.
The influence of proteinuria and albuminuria on uNGAL,
uCysC and uIL-18 concentration was previously evaluated
in a heterogeneous intensive care unit patient population
[26] where many fold increases in uNGAL and uCysC were
seen in the presence of proteinuria or albuminuria. That
study and others have highlighted that proteinuria and
albuminuria result in competitive inhibition of megalin-
cubulin mediated reabsorption of low molecular weight
urinary proteins [14, 26, 35, 36]. Thus, the increase in
Table 4 Sensitivity and specificity of 95th centile values of structural biomarker values from healthy volunteers in detecting
functional-AKI
Patients with albuminuria (n = 34) No-albuminuria (n = 16)
Biomarkers
(ng/mg Cr)
Sensitivitya Specificitya Positive
likelihood
ratioa
Negative
likelihood
ratioa
Diagnostic
odds ratioa
Sensitivitya Specificitya Positive
likelihood
ratioa
Negative
likelihood
ratioa
Diagnostic
odds ratioa
uCysC 96 (79–99) 27 (10–56) 1.3 (0.9–1.9) 0.16 (0–1.4) 8.2 (0.7–91.2) 0 (0–56) 100 (75–100) 0 1 (1–1) 0
uClu 91 (73–98) 54 (28–79) 2 (1–3.4) 0.2 (0–0.7) 12.6 (1.9–82) 0 (0–56) 100 (75–100) 0 1 (1–1) 0
Uβ2M 91 (73–98) 27 (9–56) 1.2 (0.8–1.8) 0.3 (0–1.6) 3.9 (0.5–28) 100 (43–100) 66 (39–86) 3 (1.3–6.7) 0 0
uNGAL 48 (29–57) 91 (62–98) 5.3 (0.8–35.8) 0.6 (0.4–0.9) 9.2 (1–83) 33 (6–79) 92 (64 (98) 4 (0.3–47) 0.7
(0.3–16)
5.5
(0.2–129)
uKIM-1 60 (40–78) 63 (35–85) 1.7 (0.7–3.9) 0.6 (0.3–1.2) 2.7 (0.6–12) 0 (0–56) 1 (75–100) 0 1 (1–1) 0
a Data presented with 95% CI
Serum creatinine ≥ 100% (AKI ≥ 2) is defined as functional-AKI while biomarker concentration >95th centile value in healthy volunteers (uCysC: 70 ng/mg Cr; uClu:
420 ng/mg Cr; uKIM-1 1.2 ng/mg Cr; uβ2M 166 ng/mg Cr and uNGAL: 120 ng/mg Cr) were used to define structural-AKI
Fig. 3 Sensitivity and specificity of 95th centile values of structural
biomarker values from healthy volunteers in detecting functional-AKI or
death. Serum creatinine≥ 100% (AKI≥ 2) is defined as functional-AKI while
biomarker concentration >95th centile value in healthy volunteers (uCysC:
70 ng/mg Cr; uClu: 420 ng/mg Cr; uKIM-1 1.2 ng/mg Cr; uβ2M 166 ng/
mg Cr and uNGAL: 120 ng/mg Cr) were used to define structural-AKI. Grey
and black area on the chart depicts 'Albuminuria' and 'No
albuminuria' respectively
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filtered urinary biomarker concentrations, which result
from AKI, receives a contribution from impaired absorp-
tion when albumin or other proteins are also present.
Nearly all low molecular weight proteins are believed to be
reabsorbed by megalin and cubulin-mediated endocytosis
[36].
All 50 patients included in this analysis had ingested
paraquat for deliberate self-harm and hence the change
in biomarker concentration was assumed to be solely
due to paraquat. In contrast to the present study, that of
Nejat et al. [26] recruited patients who were older and
were admitted to the intensive care unit with various
Fig. 4 Urinary albumin concentrations at different time points in controls and paraquat treated rats. Note that albumin concentration (y axis) values are
actual raw values (not logarithmic values). Y axis is formatted on log scale to improve the visibility of data points. An increase urinary albumin concentration
was observed as histopathology grades increased in paraquat treated rats. Each symbols indicate biomarker concentrations from individual rats at specific
paraquat dose levels. The histopathology grades [28] are displayed on a scale of 0 (normal) to 7 (severe) [grade 1 (white), grade 2 (yellow), grade 3 (blue),
grade 4 (green), grade 5 (red), grade 6 (purple) and grade 7 (black)]
Fig. 5 Urinary biomarker concentrations according to albuminuria in paraquat-induced nephrotoxicity in rats. This depicts urinary biomarker concentrations
at 24 h stratified by albuminuria with respect to paraquat induced nephrotoxicity. Albuminuria was defined as ACR ≥115 (μg/mg Cr) which is the 95th
centile values of ACR in control rats
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clinical presentations. Not surprisingly, 20% of patients
in that study had a prior history of CKD, which was fur-
ther limited by the use of only semi-quantitative dipstick
methods to determine proteinuria [26]. The present
study amplifies those observations with better quantita-
tion of albuminuria in a younger, presumably healthier,
cohort, with implications for evolving AKI biomarker
research [26, 35].
An additional novel approach in this study was the
recruitment of healthy young adults from the same
ethnic population to define normal biomarker reference
ranges. A similar approach is used to define myocardial
injury based on cutoff levels of cardiac troponin
obtained from healthy reference data [33, 34]. Most pre-
vious novel kidney biomarker reference ranges have
been established in control patients who were sick or
exposed to similar noxious insults but who did not de-
velop AKI [18–20]. Given that biomarker levels tend to
be higher in patient controls without AKI undergoing
cardiac catheterization or in the ICU compared to
healthy volunteers [18, 21], using patient-based control
groups to report normal levels might be misleading.
Such patients might have other age or disease-specific
co-morbidities [18] or have transient (formerly “pre-
renal”) AKI, the mild end of a continuum of renal injury
[37, 38].
Our clinical study recruited healthy young adults from
the same ethnic population (median age = 24, range 15–56
years) with no previous history of chronic kidney disease
(CKD) or other co-morbidities. The normal biomarker
range in these healthy Sri Lankan volunteers (median age =
24, range 15–56 years, Table 1 and Additional file 1: Table
S1) was similar to patients who didn’t develop AKI. The
sensitivity of these cutoffs for diagnosing functional AKI or
predicting death was examined in patients with and without
albuminuria (Fig. 3, Table 4). Excellent sensitivity (>90%)
was observed for uCysC, uClu and uβ2M in diagnosing
AKI and predicting death in the presence of albuminuria.
However, the sensitivity for uCysC and uClu in diagnosing
functional-AKI in patients who didn’t develop albuminuria
was less than 1%. In the rodent studies, we demonstrated
that biomarker cutoffs for predicting histopathological
change in paraquat-induced nephrotoxicity increased with
increasing albuminuria (Figs. 4 and 5). These differences in
biomarker concentrations between albuminuric and non-
albuminuric groups confirm that renal biomarker excretion
is increased in the presence of albuminuria and that the
cut-offs for diagnosis of AKI may differ when albuminuria
is present. Since creatinine-based criteria for defining and
staging AKI may not be appropriate in situations where
creatinine increases independently of glomerular filtration
rate as occurs early after paraquat poisoning [12], alterna-
tive definitions based on structural biomarker levels may be
needed [13–17].
Recently, we [14] defined AKI utilising both functional
and structural markers and calculated cutoffs for defin-
ing AKI and subsequent AKI staging. Generalising such
cutoffs to define AKI is challenging due to the different
non-standardised assays currently used and if other fac-
tors, for example albuminuria, influence biomarker con-
centrations independently of AKI [21–25]. This study
demonstrated that albuminuria increases the cutoff
values for outcome prediction (Table 3). If biomarkers
are used to define AKI, this study suggests that over- or
under-estimation of AKI incidence may occur and that
quantifying urinary albumin should be considered when
defining biomarker cutoffs.
Albuminuria may result from paraquat-induced glom-
erular damage, increasing filtration of albumin, or from
tubular injury, impairing reabsorption [39–41]. As we
have shown, albuminuria itself is a good diagnostic and
prognostic biomarker in paraquat-induced nephrotoxicity
consistent with previous studies [42–45]. However, to-
gether with other studies, this suggests that albuminuria-
increased biomarker excretion may lead to an increase in
the false-positive diagnosis rate for structural AKI [42, 46].
Based on these pre-clinical and clinical studies, we
propose that selection of specific biomarker cutoffs for
AKI diagnosis, staging and for risk prediction should
factor in the presence or absence of albuminuria. Al-
though these observations are based on a cohort with
paraquat poisoning which causes both glomerular [47]
and tubular injury [28], the finding is likely to be particu-
larly relevant to young patients with pre-existing albumin-
uria due to other aetiologies.
Strengths and limitations
This study has many strengths including that it is a
multi-centre prospective study recruiting previously
healthy young adults following a single nephrotoxic in-
sult, with quantification of albuminuria and the estab-
lishment of biomarker ranges in healthy subjects. The
study also has several limitations. The sample size of
healthy control subjects was small (n = 63) and the 95th
centile values used to define structural AKI need to be
validated. Nevertheless, a sensitivity analysis using alter-
native cut offs (97.5 or 99%) didn’t change the conclu-
sions. Thus healthy population cutoffs to define
structural AKI may have clinical utility once validated in
larger populations. Further studies are clearly warranted
to examine this methodology in AKI biomarker
research.
Conclusion
Albuminuria increased excretion of most low-molecular
weight urinary protein biomarkers following paraquat
poisoning and enhanced biomarker sensitivity in detec-
tion of functional AKI and in predicting poor outcome.
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Biomarker performance was reduced with altered sensi-
tivities and increased cutoffs in the presence of albumin-
uria suggesting that diagnostic and predictive biomarker
cutoffs need to be qualified in the presence of
albuminuria.
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